Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mihály Medvegy

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Ideggyogyaszati Szemle|January 8, 2013
[Rivaroxaban in prevention of stroke in patients with atrial fibrillation]Gábor Simonyi, Mihály Medvegy
Cardiology and Therapy|April 3, 2021
Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19)Mihály Medvegy, Gábor Simonyi
Orvosi Hetilap|February 5, 2013
[Instrumental therapy of drug-resistant hypertension]Gábor Simonyi, J Róbert Bedros, Mihály Medvegy
Acta Physiologica Hungarica|September 7, 2011
Non-ST elevation myocardial infarction: a new pathophysiological concept could solve the contradiction between accepted cause and clinical observationsMihály Medvegy, G Simonyi, N Medvegy, et al.
Orvosi Hetilap|May 5, 2020
Real-world adherence to oral anticoagulants in atrial fibrillationGábor Simonyi, András Paksy, Réka Várnai, et al.
Orvosi Hetilap|February 4, 2024
[Five-year persistence of statins after acute myocardial infarction in statin-naïve patients]Gábor Simonyi, Tamás Ferenci, Ervin Finta, et al.
Orvosi Hetilap|February 29, 2012
[The pharmacological treatment of obesity: past, present and future]Gábor Simonyi, Gyula Pados, Mihály Medvegy, et al.
Orvosi Hetilap|August 27, 2023
[One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients]Gábor Simonyi, Tamás Ferenci, Ervin Finta, et al.
Orvosi Hetilap|September 5, 2017
[One year persistence of free and fixed dose combinations of perindopril/amlodipine]Gábor Simonyi, Tamás Ferenci, Mihály Medvegy, et al.
Orvosi Hetilap|March 26, 2019
[One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation]Gábor Simonyi, Tamás Ferenci, Ervin Finta, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Ideggyogyaszati Szemle|January 8, 2013
[Rivaroxaban in prevention of stroke in patients with atrial fibrillation]Gábor Simonyi, Mihály Medvegy
Cardiology and Therapy|April 3, 2021
Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19)Mihály Medvegy, Gábor Simonyi
Orvosi Hetilap|February 5, 2013
[Instrumental therapy of drug-resistant hypertension]Gábor Simonyi, J Róbert Bedros, Mihály Medvegy
Acta Physiologica Hungarica|September 7, 2011
Non-ST elevation myocardial infarction: a new pathophysiological concept could solve the contradiction between accepted cause and clinical observationsMihály Medvegy, G Simonyi, N Medvegy, et al.
Orvosi Hetilap|May 5, 2020
Real-world adherence to oral anticoagulants in atrial fibrillationGábor Simonyi, András Paksy, Réka Várnai, et al.
Orvosi Hetilap|February 4, 2024
[Five-year persistence of statins after acute myocardial infarction in statin-naïve patients]Gábor Simonyi, Tamás Ferenci, Ervin Finta, et al.
Orvosi Hetilap|February 29, 2012
[The pharmacological treatment of obesity: past, present and future]Gábor Simonyi, Gyula Pados, Mihály Medvegy, et al.
Orvosi Hetilap|August 27, 2023
[One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients]Gábor Simonyi, Tamás Ferenci, Ervin Finta, et al.
Orvosi Hetilap|September 5, 2017
[One year persistence of free and fixed dose combinations of perindopril/amlodipine]Gábor Simonyi, Tamás Ferenci, Mihály Medvegy, et al.
Orvosi Hetilap|March 26, 2019
[One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation]Gábor Simonyi, Tamás Ferenci, Ervin Finta, et al.
Pageof 2